To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

June 11, 2024

Watch Brain Cancer Experts Share Progress on Treatment Options

2024 EBCI KAYTO Logo

If you missed our "2024 Know All Your Treatment Options" (KAYTO24) patient disease education event and webinar, you can still hear from the experts on topics such as treatments, diagnostics, and progress in the brain cancer space.

All of the expert videos are now available on the End Brain Cancer Initiative website! Click the button below to access these free patient disease education presentations and videos now.

Dr. Hanft photo
Dr. Simon Hanft
Westchester Medical Center
Section Chief of Neurosurgical Oncology
Eric Perreault head shot
Eric Perreault
Dr. Dewey
Dr. Jonathan Dewey
Servier Pharmaceuticals
Senior Medical Director for Solid Tumors
Vyshak Venur, MD
Dr. Vyshak Venur
Fred Hutch Cancer Center
Oncologist & Co-Director for Clinical Research
Senior VP Sales - Americas ZAP
Stephanie Key
Commercial Clinical Director
Dr Nick Avgeropoulos
Dr. Nicholas Avgeropoulos
Therapeutic Area Lead, CNS Cancers, Global Medical Affairs

Click below to support increased Patient Access.

Thank You to Presenting Sponsors GammaTile® & Kiyatec

Gamma Tile Official Logo - 2024
KiyateclogovBRIGHT 1920w.jpg 1

This patient disease education event and webinar was made possible by presenting sponsors GammaTile® and Kiyatec, as well as other patient disease education sponsors, including Ono Pharmaceutical USA, Northwest Biotherapeutics, Great Purpose Productions, WHIM Social, and more.

GammaTile®  is a radiation treatment specifically designed for use inside the brain and is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. Since its full market release in the United States in March 2020, GammaTile® has been offered in over 100 leading institutions, with more centers being added each month. Learn more at

Kiyatec is a functional precision oncology company that measures the response of individual patients’ live cancer cells with its innovative 3D cell culture technology platform. Kiyatec’s 3D Predict Glioma test helps to predict which drugs will be most effective by observing how a patient’s cancer cells react to different chemotherapies. Learn more at

Sponsor logos

EBCI app on cell phone


Scan or click the QR code to download the App now!


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram